Thursday, May 7, 2020
Dahl Arts Center
713 7th St, Rapid City, SD 577012
Keynote Speaker: Alana L. Welm, PhD
Light Hors D’oeuvres || Wellness Expo with local companies || Art Galleries Open Until 6 p.m.
Join us for a public event for breast cancer survivors, breast cancer patients, caregivers, loved ones and medical professionals. Enjoy talking to local companies about staying healthy year-round and hear from a leading breast cancer researcher on groundbreaking work underway that will change how breast cancer is treated.
Dr. Welm’s research focuses on better understanding the biology of metastasis (cancer that spreads beyond the breast) in order to develop new therapies and create patient-derived models that more accurately reflect behavior of tumors and response to therapy. Attendees will have an opportunity to ask questions of Dr. Welm.
Pictures from 2019 Power of Research (photos courtesy of Henry Roy Photography)
Dr. Welm completed her PhD in Cell and Molecular Biology at Baylor College of Medicine in Houston, TX under the supervision of Gretchen Darlington, PhD. She then went on to conduct postdoctoral training in nobel laureate Dr. J. Michael Bishop’s laboratory at the University of California, San Francisco where her work focused on developing new models of breast cancer metastasis. Dr. Welm started her laboratory at the University of Utah’s Huntsman Cancer Institute in 2007, and was promoted to Associate Professor with tenure in 2013 and to full Professor in 2019. She now holds the Ralph E. and Willia T. Main Presidential Endowed Chair in Cancer Research and is Co-Director of the Cell Response and Regulation Program at Huntsman Cancer Institute.
The research in Dr. Welm’s laboratory is focused on solving the problem of breast cancer metastasis using in vivo modeling of mouse and human breast cancers. Dr. Welm’s group discovered that the Ron kinase pathway is an important facilitator of breast cancer metastasis through its unique dual function in tumor cells and in resident macrophages. Current areas of research include (1) pre-clinical studies of various Ron inhibitors for treatment and prevention of metastatic breast cancer; (2) pre-clinical and early clinical studies of the Ron/Met inhibitor BMS777607/ASLAN002 in bone metastatic cancers; (3) discovering molecular mechanisms by which Ron kinases promote metastasis through cell-autonomous and non cell-autonomous pathways; and (4) refining “precision medicine” for metastatic breast cancer using functional assays in patient-derived breast tumor grafts.